Low and adequately dosed 6-thioguanine: Not so bad after all

Inflammatory Bowel Diseases

Volumn 14, Issue 8, 2008, Pages 1166-1167

  de Boer, Nanne K H ^a   Jharap, Bindia ^a   Mulder, Chris J ^a   van Bodegraven, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHYLTRANSFERASE; TIOGUANINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; ESOPHAGUS VARICES; HEPATITIS C; HUMAN; LETTER; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HYPERPLASIA; LIVER TOXICITY; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; ULCERATIVE COLITIS;

ANTIMETABOLITES, ANTINEOPLASTIC; COLITIS, ULCERATIVE; HUMANS; HYPERPLASIA; LIVER; LIVER DISEASES; THIOGUANINE;

EID: 49749129258     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20437     Document Type: Letter

References (9)

1. Fritz E, Wrba F, Knoflach P. Variceal hemorrhage in a patient with ulcerative colitis treated with 6-thioguanine. Inflamm Bowel Dis. 2008; (in press).
2. de Boer NK, Remisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006;73:25-31.
3. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787-797.
4. de Boer NK, Tuynman H, Bloemena E, et al. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: Prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol. 2008; (in press).
5. Buster EH, van Vuuren M, Zondervan PE, et al. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur J Gastroenterol Hepatol. 2008;20:68-72.
6. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;152:298-303.
7. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol. 2005;43:303-309.
8. de Boer NK, Zondervan PE, Gilissen LP, et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis. 2008;40:108-113.
9. Jharap B, Mulder CJ, den Hartog G, et al. Adequately dosed 6-TG use in chronic intestinal inflammation is not associated with nodular regenerative hyperplasia: a series of 73 liver biopsies. Gastroenterology. 2007;132(suppl 2):S1128 (A-179).